EP0493533A4 - Inhibition of cell growth by keratan sulfate, chondroitin sulfate, dermatan sulfate and other glycans - Google Patents

Inhibition of cell growth by keratan sulfate, chondroitin sulfate, dermatan sulfate and other glycans

Info

Publication number
EP0493533A4
EP0493533A4 EP19900917627 EP90917627A EP0493533A4 EP 0493533 A4 EP0493533 A4 EP 0493533A4 EP 19900917627 EP19900917627 EP 19900917627 EP 90917627 A EP90917627 A EP 90917627A EP 0493533 A4 EP0493533 A4 EP 0493533A4
Authority
EP
European Patent Office
Prior art keywords
sulfate
glycans
inhibition
cell growth
keratan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19900917627
Other versions
EP0493533A1 (en
Inventor
Diane M. Snow
Jerry Silver
Adrian Harel
Dikla Roufa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Case Western Reserve University
Gliatech Inc
Original Assignee
Case Western Reserve University
Gliatech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Case Western Reserve University, Gliatech Inc filed Critical Case Western Reserve University
Publication of EP0493533A1 publication Critical patent/EP0493533A1/en
Publication of EP0493533A4 publication Critical patent/EP0493533A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP19900917627 1989-10-27 1990-10-26 Inhibition of cell growth by keratan sulfate, chondroitin sulfate, dermatan sulfate and other glycans Withdrawn EP0493533A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42837489A 1989-10-27 1989-10-27
US428374 1989-10-27

Publications (2)

Publication Number Publication Date
EP0493533A1 EP0493533A1 (en) 1992-07-08
EP0493533A4 true EP0493533A4 (en) 1992-10-28

Family

ID=23698624

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19900917627 Withdrawn EP0493533A4 (en) 1989-10-27 1990-10-26 Inhibition of cell growth by keratan sulfate, chondroitin sulfate, dermatan sulfate and other glycans

Country Status (4)

Country Link
EP (1) EP0493533A4 (en)
AU (1) AU6872691A (en)
CA (1) CA2071898A1 (en)
WO (1) WO1991006303A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605938A (en) 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
US7008783B1 (en) 1992-09-22 2006-03-07 Maruha Corporation Gene encoding chondroitinase ABC and uses therefor
US6140071A (en) * 1994-01-27 2000-10-31 Somatogen, Inc. Proteins with mutations to decrease N-terminal methylation
ATE256137T1 (en) * 1994-12-01 2003-12-15 Seikagaku Kogyo Co Ltd KERATANESULFATOLIGOSACCHARIDE FRACTION AND MEDICATION CONTAINING SAME
EP0747470A1 (en) 1995-06-08 1996-12-11 The Procter & Gamble Company Cleaning compositions comprising keratanase
EP0747469A1 (en) * 1995-06-08 1996-12-11 The Procter & Gamble Company Cleaning compositions comprising chondroitinase
FR2787329B1 (en) * 1998-12-17 2001-02-09 Aventis Pharma Sa NEW THERAPEUTIC APPLICATION OF LOW MOLECULAR WEIGHT HEPARINS
AU6557299A (en) 1999-01-07 2000-07-13 Seikagaku Corporation Method for producing oligosaccharide, and novel oligosaccharide and pharaceutical composition containing the same
US6083933A (en) * 1999-04-19 2000-07-04 Stellar International Inc. Treatment of cystitis-like symptoms with chondroitin sulfate following administration of a challenge solution
EP1074260B1 (en) 1999-07-21 2004-02-18 Seikagaku Corporation IL-12 Production inhibitor
WO2002060471A2 (en) * 2001-01-30 2002-08-08 Ich Productions Limited Ligands for receptor-like protein tyrosine phosphatases
JP4749667B2 (en) 2001-08-13 2011-08-17 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド Materials and methods for promoting neural tissue repair
GB0205022D0 (en) * 2002-03-04 2002-04-17 Univ Cambridge Tech Materials and methods for the treatment of cns damage
DE60336341D1 (en) 2002-05-04 2011-04-21 Acorda Therapeutics Inc COMPOSITIONS AND METHODS FOR PROMOTING NEURONAL GROWTH
US20040161476A1 (en) 2003-02-19 2004-08-19 Hahn Sungtack Samuel Cystitis treatment with high dose chondroitin sulfate
US7511026B2 (en) * 2003-03-25 2009-03-31 Seikagaku Corporation Therapeutic agent for nerve damage
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
ES2887949T3 (en) 2003-05-16 2021-12-29 Acorda Therapeutics Inc Proteoglycan-degrading mutants for CNS treatment
CA2566731C (en) 2004-05-18 2012-07-24 Acorda Therapeutics, Inc. Methods of purifying chondroitinase and stable formulations thereof
WO2006111348A1 (en) * 2005-04-18 2006-10-26 Abbott Gmbh & Co. Kg Use of heparin and heparin derivatives for modulating the neurite growth-controlling nogo receptor
CA2623635C (en) 2005-09-26 2013-04-02 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
US7722864B2 (en) 2006-10-10 2010-05-25 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants
US20110059508A1 (en) 2007-06-29 2011-03-10 National University Corporation Nagoya University Improving agent for dysfunction due to neuropathy and rho kinase activation inhibitor
WO2010003023A2 (en) * 2008-07-01 2010-01-07 Zacharon Pharmaceuticals, Inc. Heparan sulfate inhibitors
WO2011082175A2 (en) * 2009-12-31 2011-07-07 Zacharon Pharmaceuticals, Inc. Glycosaminoglycan inhibitors
US11549000B2 (en) 2015-12-18 2023-01-10 Tega Therapeutics, Inc. Cellular glycosaminoglycan compositions and methods of making and using

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3441835A1 (en) * 1984-11-15 1986-05-22 Luitpold-Werk Chemisch-pharmazeutische Fabrik GmbH & Co, 8000 München Haemostatic composition
EP0257003A2 (en) * 1986-07-09 1988-02-24 Kabi Pharmacia AB An enzyme preparation capable of degrading glycosaminoglycan, and a method for producing said preparation
WO1988001280A1 (en) * 1986-08-21 1988-02-25 Board Of Regents, The University Of Texas System Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness or metastatic profusion
WO1990006755A1 (en) * 1988-12-15 1990-06-28 Glycomed Incorporated Heparin fragments as inhibitors of smooth muscle cell profileration

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5299207A (en) * 1976-02-16 1977-08-19 Kaken Pharmaceut Co Ltd Remedy for cattle diarrhea
US4640912A (en) * 1983-06-09 1987-02-03 Hausman Marvin S Administration of "active" chondroitin sulfate A and "active" chondroitin sulfate C or mixtures thereof to mammals including humans
SE8304836D0 (en) * 1983-09-09 1983-09-09 Pharmacia Ab SETTLE TO DETERMINE CHANGES IN LEDS
US4808570A (en) * 1984-02-24 1989-02-28 University Of California Compositions and method for improving wound healing
US4745098A (en) * 1984-02-24 1988-05-17 The Regents Of The University Of California Compositions and method for improving wound healing
US4710493A (en) * 1984-08-14 1987-12-01 Albert Landsberger Therapeutic agent for the use in cancer treatment
IT1208509B (en) * 1985-03-13 1989-07-10 Mediolanum Farmaceutici Srl PROCESS FOR THE PRODUCTION OF NATURALLY PURE NATURAL EPARAN SULPHATE AND DERMATAN SULPHATE AND THEIR PHARMACEUTICAL USE.
SE8501723L (en) * 1985-04-09 1986-10-10 Pharmacia Ab PREPARATION TO BE USED IN TREATMENT OF LED INFLAMMATION
US4829000A (en) * 1985-08-30 1989-05-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Reconstituted basement membrane complex with biological activity
US4696816A (en) * 1985-11-07 1987-09-29 Brown Mark D Method for treating intervertebral disc displacement with enzymes
US4956348A (en) * 1986-02-19 1990-09-11 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with cyclic nucleotides
US4760131A (en) * 1986-04-23 1988-07-26 Collagen Corporation Wound-healing composition
US4945086A (en) * 1988-05-03 1990-07-31 The Board Of Trustees Of The Leland Stanford Junior University Smooth muscle cell growth inhibitor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3441835A1 (en) * 1984-11-15 1986-05-22 Luitpold-Werk Chemisch-pharmazeutische Fabrik GmbH & Co, 8000 München Haemostatic composition
EP0257003A2 (en) * 1986-07-09 1988-02-24 Kabi Pharmacia AB An enzyme preparation capable of degrading glycosaminoglycan, and a method for producing said preparation
WO1988001280A1 (en) * 1986-08-21 1988-02-25 Board Of Regents, The University Of Texas System Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness or metastatic profusion
WO1990006755A1 (en) * 1988-12-15 1990-06-28 Glycomed Incorporated Heparin fragments as inhibitors of smooth muscle cell profileration

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
DEVELOPMENT BIOLOGY, vol. 138, no. 2, April 1990, pages 359-376; D.M. SNOW et al.: "Molecular and cellular characterization on the glial roof plate of the spinal cord and optic tectum: A possible role for a proteoglycan in the development of an axon barrier" *
EXPERIMENTAL CELL RESEARCH, vol. 175, no. 2, April 1988, pages 229-247; G. MUGNAI et al.: "Ganglioside-dependent adhesion events of human neuroblastoma cells regulated by the RGDS-dependent fibronectin receptor anf proteoglycans" *
EXPERIMENTAL NEUROLOGY, vol. 109, no. 1, July 1990, pages 111-130; D.M. SNOW et al.: "Sulfated proteoglycans in astroglial barriers inhibit neurite outgrowth in vitro" *
FEDERATION PROCEEDINGS, vol. 44, no. 2, February 1985, pages 386-393; B. CATERSON et al.: "Production and characterization of monoclonal antibodies directed against connective tissue proteoglycans" *
INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE, vol. 7, no. 2, 1989, pages 133-143; G.M. GILAD et al.: "Effects of glycosaminoglycans and proteinase inhibitors on astroglia-induced detachment of cultured rat cerebellar neurons" *
JOURNAL OF CELLULAR PHYSIOLOGY, vol. 135, no. 2, May 1988, pages 293-300; D.H. DAMON et al.: "Sulfated glycosaminoglycans modify growth factor-induced neurite outgrowth in PC12 cells" *
JOURNAL OF NEUROSCIENCE RESEARCH, vol. 19, no. 4, April 1988, pages 428-439; N.G. CARRI et al.: "Differential outgrowth of retinal neurites on purified extracellular matrix molecules" *
See also references of WO9106303A1 *
THE JOURNAL OF CELL BILLOGY, vol. 105, no. 6, part 1, December 1987, pages 2511-2521; PERRIS et al.: "Amphibian neural crest cell migration on purified extracellular matrix components: A chondroitin sulfate proteoglycan inhibits locomotion on fibronectin substrates" *
THE JOURNAL OF CELL BIOLOGY, vol. 101, 1985, pages 53-59; M. ZANETTI et al.: "Two subpopulations of differentiated chondrocytes identified with a monoclonal antibody to keretan sulfate" *
THE JOURNAL OF CELL BIOLOGY, vol. 105, no. 6, part 1, December 1987, pages 2511-2521; PERRIS et al.: "Amphibian neural crest cell migration on purified extracellular matrix components: A chondroitin sulfate proteoglycan inhibits locomotion on fibronectin substrates" *
THE JOURNAL OF NEUROSCIENCE, vol. 3, no. 11, November 1983, pages 2324-2335; S. CARBONETTO et al.: "Nerve fiber growth in culture on fibronectin, collagen, and glycosaminoglycan substrates" *

Also Published As

Publication number Publication date
CA2071898A1 (en) 1991-04-28
EP0493533A1 (en) 1992-07-08
AU6872691A (en) 1991-05-31
WO1991006303A1 (en) 1991-05-16

Similar Documents

Publication Publication Date Title
EP0493533A4 (en) Inhibition of cell growth by keratan sulfate, chondroitin sulfate, dermatan sulfate and other glycans
AU555747B2 (en) Chondroitin sulfate and sodium hyaluronate composition
GB2244513B (en) Casement hinges
AU2561792A (en) Cell-type specific heparan sulfate proteoglycans and their uses
GB8922020D0 (en) Hinges
GB2244298B (en) Structural assemblies and cavity closers
GB2229766B (en) Door hinge system
AU5915790A (en) Synthetic chondroitin sulfate proteoglycan and process for producing the same
GB2231616B (en) Casement fastener
GB2238827B (en) Hinge
GB8815032D0 (en) Doors & methods of ensuring their security
GB8806244D0 (en) Cupboard door manufacture
GB2248877B (en) Door closer and method of making the door closer
GB2232199B (en) Hinge
IL92439A0 (en) Multi-leaf hinge
GB2216592B (en) Casement fastener
GB2228283B (en) Doors
GB9005160D0 (en) Hinge
AP9000210A0 (en) Solid thiocarbonates and methods of
CS446088A1 (en) Adjustable door hinge
CA62235S (en) Doorstop
GB8827082D0 (en) Door closers
GB2174751B (en) Hinges for doors and the like
HUT57361A (en) Door and window structure particularly workshop- or garage-door
AU566004B3 (en) Door stop and stay

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19920422

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19920908

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19931220

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19950411